Work

Abstract CT130: Initial results from a phase 1 study of PHST001, a macrophage activating anti-CD24 antibody, in patients with advanced/metastatic solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct130

Authors: Stephane Champiat, Ulka Vaishampayan, Michael Cecchini, Oliver Dorigo, Anthony El-Khoueiry, Gina Fleming, Niharika Mettu, Michael J. Dennis, Elizabeth Davis, Susan Luebbe, Jen Cao, Roy Maute, Raphael Rousseau, Kyriakos Papadopoulos

Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, Yale University, Stanford Cancer Institute, Stanford University, University of Southern California, USC Norris Comprehensive Cancer Center, University of Chicago, University of Chicago Medical Center, Duke Cancer Institute, Dana-Farber Cancer Institute, Vanderbilt University Medical Center, South Texas Accelerated Research Therapeutics

Language: English

Topic: Phagocytosis and Immune Regulation

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154698190

Cites:

Cited by:

Related to: